Healthcare Reform impact TBD

Share this article:

For many potential patients, 2014 started with a new title: insured. What this means and who it encompasses, however, is up for grabs.

As noted by the Wall Street Journal, progress has been shaky since the Affordable Care Act made its way through Congress, including the autumn spectacle in which left many applicants on the sidelines as it struggled to manage even a portion of anticipated web traffic.

Assessing healthcare reform's impact requires hammering out a lot of what-ifs. Right now, for example, insurers told the Journal that web problems probably kept younger—and therefore healthier and less financially burdensome—customers from signing up for coverage. There is still time to sign up for insurance, which means younger, healthier patients who are putting money into a system they are not disproportionately drawing from can still join up and drive data in a new direction. At the same time, there have been reports of grumbling among the already-insured about rising deductibles, but how and if that discontent translates into a dialing up or down of healthcare-system use is one for the what-if pile.

At the same time, Health Affairs published in December yet another study that showed most Americans do not understand basic health insurance concepts like deductibles and data. The Urban Institute survey the researchers used essentially put all newly insured in the same context as a just-employed 20-something who needs to learn how insurance works and just how much coverage they need.

None of this data, however, anticipates how these factors will influence patient behavior and medical care consumption, and is a question that has bedeviled researchers since even before insurance became a universal requirement.

Share this article:
You must be a registered member of MMM to post a comment.

Next Article in Business Briefs

Email Newsletters

MM&M Future Leaders

Register now

Early bird $1,950 before 31 October 2014

*Group discounts available on request 


Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Business Briefs

Novartis said to be stepping out of HCV

Novartis is said to have relinquished rights to an investigational hep. C treatment, signaling its exit from the therapeutic space, according to a former partner's announcement.

Monday Moves: September 15

Hires and promotions for manufacturers, regulatory and agencies

Kantar acquires Evidências, expands Brazilian presence

The company's acquisition signals the growing importance of understanding the Brazilian healthcare market and evidence-based healthcare management services.